COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Genetics of CRP in Families With Myocardial Infarction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00064519
Recruitment Status : Completed
First Posted : July 10, 2003
Last Update Posted : September 24, 2015
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Ulrich Broeckel MD, Medical College of Wisconsin

Brief Summary:
To investigate the genetics of C reactive protein in families with myocardial infarction.

Condition or disease
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Infarction

Detailed Description:


Coronary artery disease (CAD) and myocardial infarction (MI) are the leading causes of death in the Western world. Numerous epidemiological studies have demonstrated the impact of various risk factors, such as arterial hypertension, hypercholesterolemia and diabetes mellitus. While these risk factors are partly under genetic control, a positive family history remains an additional independent predictor of CAD, suggesting the presence of as yet unidentified susceptibility loci. Given the enormous public health burden of CAD, there is significant interest in identifying its specific genetic foundations. As intensive experimental investigations continue, the inflammatory component of the disease process leading to atherosclerosis evolves as a key aspect in the disease process. Recent evidence demonstrates that systemic markers of inflammation such as C reactive protein (CRP) can predict those at high risk of coronary events. CRP emerges with much attention as both a diagnostic marker and therapeutic target with serum levels determined to a significant extent by genetic factors.


To elucidate the genetic basis of the inflammatory component of myocardial infarction and the regulation of C reactive protein, a gene function oriented evaluation of candidate genes will be conducted. Therefore the specific aims are as follows, 1. Identify positional candidate genes within regions identified for MI and CRP which are functionally related to inflammation and inflammatory processes. Sequence variation in selected candidate genes will be identified. 2. Evaluate the effect of these variants with regard to MI and CRP in two different ethnic populations: a family set of European Caucasians and a population-based, Hispanic family dataset. The role of CRP will be evaluated as a predictor of cardiovascular events in the study populations. Since clinical follow up data are available on both study populations, the extent to which CRP contributes to an increased risk for cardiovascular events will be analyzed.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1406 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Study Start Date : July 2003
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Families with MI

In conjunction with collaborators in Germany, we have established one of the largest collections of families with MI, comprising 1,406 individuals in 513 Western-European families. Based on this collection, our total genome scan and linkage analysis has identified a region on chromosome 14 with a significant linkage signal for myocardial infarction (LOD = 3.9, pointwise P = 0.00015, genome-wide P < 0.05)5. Preliminary results from an association study in a subset of these families has identified a small set of single nucleotide polymorphisms (SNPs) within candidate genes in this region as being suggestively associated with MI.

No drugs are to be administre

Primary Outcome Measures :
  1. Association of markers with cardiovascular event [ Time Frame: Event recorded at time of recruitment ]

Biospecimen Retention:   Samples With DNA

i.) Blood: A blood sample (30 cc, ~2 tablespoons) will be drawn. This will take place in the catheterization lab at the end of the catheterization procedure or by using standard venipuncture technique during a clinic visit or at community outreach events when feasible.

ii.) Buccal Swab: The participant uses specially prepared cotton swabs (called buccal swabs) to rub in a circular motion on the inside of both cheeks. The swabs collect cheek cells that can be processed to obtain DNA.

iii.) Saliva: A saliva sample is obtained by having the participant spit in a special vial specifically designed for genetic testing. The participant will continue to spit into the vial until it contains 2 ml (about 1 teaspoon) of saliva.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals having CAD and individuals not having CAD
  1. First Part DNA Collection

    a.) Inclusion Criteria i.) Being 18 years of age or older. ii.) Having had a cardiac catheterization procedure performed or undergoing one in the near future.

    iii.) A person having a family history of coronary artery disease and having at least one family member that has had a cardiac catheterization that is willing to participate.

    iv.) Having coronary artery (right, left main, circumflex, marginal and/or diagonal) blockage in a specific portion of the vessel (ostial, proximal, mid and/or distal).

    b.) Exclusion Criteria i.) Having had a bone marrow transplant.

  2. Second Part Coronary Collateralization and Extended Phenotyping a.) Inclusion Criteria i.) Having participated in DNA collection. ii.) Having at least one coronary artery with 100% blockage or iii.) Having normal coronary arteries with no blockage b.) Exclusion Criteria i.) Having received a diagnosis and treatment for kidney disease, cancer, myocardial infarction within the last three (3) months.

ii.) Having a heart transplant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00064519

Sponsors and Collaborators
Medical College of Wisconsin
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: Ulrich Broeckel Medical College of Wisconsin
Layout table for additonal information
Responsible Party: Ulrich Broeckel MD, Professor of Pediatrics, Medical College of Wisconsin Identifier: NCT00064519    
Other Study ID Numbers: 1225
R01HL074321 ( U.S. NIH Grant/Contract )
First Posted: July 10, 2003    Key Record Dates
Last Update Posted: September 24, 2015
Last Verified: September 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Myocardial Infarction
Coronary Disease
Cardiovascular Diseases
Pathologic Processes
Myocardial Ischemia
Vascular Diseases